Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Sublocade buprenorphine Opioid use disorder, treatment Reimburse with clinical criteria and/or conditions Complete
Suboxone Buprenorphine/naloxone Opioid drug dependence (Substitution treatment) List with clinical criteria and/or conditions Complete
Sunosi solriamfetol Excessive daytime sleepiness (narcolepsy) Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Sunosi solriamfetol Excessive daytime sleepiness Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Sunvepra Asunaprevir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete
Sutent Sunitinib malate Pancreatic Neuroendocrine Tumour Reimburse with clinical criteria and/or conditions Complete
Sutent Sunitinib Gastrointestinal stromal tumour (GIST) List with clinical criteria and/or conditions Complete
Sutent Sunitinib malate Cancer, Metastatic renal cell carcinoma Do not list Complete
Sylvant Siltuximab Multicentric Castleman's disease (MCD) Reimburse with clinical criteria and/or conditions Complete
Symdeko tezacaftor/ivacaftor Cystic fibrosis, F508del mutation(s) Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Symtuza Darunavir/cobicistat/emtricitabine/tenofovir alafenamide HIV-1 infection Reimburse with clinical criteria and/or conditions Complete
Synjardy Empagliflozin and metformin Diabetes mellitus (Type 2) Reimburse with clinical criteria and/or conditions Complete
Tabrecta capmatinib Metastatic non-small cell lung cancer (NSCLC) Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Tafinlar Dabrafenib Metastatic Melanoma Reimburse with clinical criteria and/or conditions Complete
Tafinlar & Mekinist in combo Dabrafenib & Trametinib in combo Melanoma Adjuvant Therapy Reimburse with clinical criteria and/or conditions Complete
Tafinlar & Mekinist in combo Dabrafenib & Trametinib in combo Non-Small Cell Lung Cancer Do not reimburse Complete
Tafinlar & Mekinist in combo Dabrafenib & Trametinib in combo Metastatic Melanoma Reimburse with clinical criteria and/or conditions Complete
Tafinlar and Mekinist dabrafenib and trametinib Pediatric high-grade glioma with BRAF V600E Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Tafinlar and Mekinist dabrafenib and trametinib Pediatric low-grade glioma with BRAF V600E Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Tafinlar and Mekinist Dabrafenib and Trametinib NSCLC BRAF V600 Reimburse with clinical criteria and/or conditions Complete
Tafinlar-Mekinist dabrafenib trametinib Advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation Pending
Tagrisso Osimertinib Non-Small Cell Lung Cancer (NSCLC) (first line) Reimburse with clinical criteria and/or conditions Complete
Tagrisso osimertinib Non-small cell lung cancer Active
Tagrisso Osimertinib Non-Small Cell Lung Cancer Reimburse with clinical criteria and/or conditions Complete
Tagrisso osimertinib Non-small cell lung cancer Reimburse with clinical criteria and/or conditions Complete